Altered metabolism of tacrolimus in hepatic veno-occlusive disease

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Tacrolimus is widely used for the prophylaxis and treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation (HSCT) and graft rejection in solid organ transplantation. The metabolism of tacrolimus has been reported to be impaired in association with liver dysfunction, mostly as documented in liver transplant recipients. Hepatic veno-occlusive disease (VOD) is one of the serious complications after allogeneic HSCT. It is characterized by jaundice, fluid retention, and painful hepatomegaly, caused by endothelial cell injury resulting from the toxicity of the conditioning regimen. The impaired metabolism of tacrolimus in hepatic VOD has not previously been reported in the literature. Here, we report the notable alteration in the metabolism of tacrolimus in two patients with hepatic VOD, in whom the half-lives of tacrolimus were markedly prolonged (288 and 146 h).

Original languageEnglish
Pages (from-to)1215-1217
Number of pages3
JournalTransplant International
Volume18
Issue number10
DOIs
Publication statusPublished - 2005 Oct

Fingerprint

Hepatic Veno-Occlusive Disease
Tacrolimus
Hematopoietic Stem Cell Transplantation
Graft Rejection
Hepatomegaly
Organ Transplantation
Graft vs Host Disease
Jaundice
Liver Diseases
Endothelial Cells
Liver
Wounds and Injuries

Keywords

  • Hematopoietic stem cell transplantation
  • Hepatic VOD
  • Tacrolimus

ASJC Scopus subject areas

  • Transplantation

Cite this

Altered metabolism of tacrolimus in hepatic veno-occlusive disease. / Mori, Takehiko; Shimizu, Takayuki; Yamazaki, Rie; Nakazato, Tomonori; Ikeda, Yasuo; Okamoto, Shinichiro.

In: Transplant International, Vol. 18, No. 10, 10.2005, p. 1215-1217.

Research output: Contribution to journalArticle

@article{8c689d31c9ee4d0dbb95e6f412f0fb1b,
title = "Altered metabolism of tacrolimus in hepatic veno-occlusive disease",
abstract = "Tacrolimus is widely used for the prophylaxis and treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation (HSCT) and graft rejection in solid organ transplantation. The metabolism of tacrolimus has been reported to be impaired in association with liver dysfunction, mostly as documented in liver transplant recipients. Hepatic veno-occlusive disease (VOD) is one of the serious complications after allogeneic HSCT. It is characterized by jaundice, fluid retention, and painful hepatomegaly, caused by endothelial cell injury resulting from the toxicity of the conditioning regimen. The impaired metabolism of tacrolimus in hepatic VOD has not previously been reported in the literature. Here, we report the notable alteration in the metabolism of tacrolimus in two patients with hepatic VOD, in whom the half-lives of tacrolimus were markedly prolonged (288 and 146 h).",
keywords = "Hematopoietic stem cell transplantation, Hepatic VOD, Tacrolimus",
author = "Takehiko Mori and Takayuki Shimizu and Rie Yamazaki and Tomonori Nakazato and Yasuo Ikeda and Shinichiro Okamoto",
year = "2005",
month = "10",
doi = "10.1111/j.1432-2277.2005.00204.x",
language = "English",
volume = "18",
pages = "1215--1217",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Altered metabolism of tacrolimus in hepatic veno-occlusive disease

AU - Mori, Takehiko

AU - Shimizu, Takayuki

AU - Yamazaki, Rie

AU - Nakazato, Tomonori

AU - Ikeda, Yasuo

AU - Okamoto, Shinichiro

PY - 2005/10

Y1 - 2005/10

N2 - Tacrolimus is widely used for the prophylaxis and treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation (HSCT) and graft rejection in solid organ transplantation. The metabolism of tacrolimus has been reported to be impaired in association with liver dysfunction, mostly as documented in liver transplant recipients. Hepatic veno-occlusive disease (VOD) is one of the serious complications after allogeneic HSCT. It is characterized by jaundice, fluid retention, and painful hepatomegaly, caused by endothelial cell injury resulting from the toxicity of the conditioning regimen. The impaired metabolism of tacrolimus in hepatic VOD has not previously been reported in the literature. Here, we report the notable alteration in the metabolism of tacrolimus in two patients with hepatic VOD, in whom the half-lives of tacrolimus were markedly prolonged (288 and 146 h).

AB - Tacrolimus is widely used for the prophylaxis and treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation (HSCT) and graft rejection in solid organ transplantation. The metabolism of tacrolimus has been reported to be impaired in association with liver dysfunction, mostly as documented in liver transplant recipients. Hepatic veno-occlusive disease (VOD) is one of the serious complications after allogeneic HSCT. It is characterized by jaundice, fluid retention, and painful hepatomegaly, caused by endothelial cell injury resulting from the toxicity of the conditioning regimen. The impaired metabolism of tacrolimus in hepatic VOD has not previously been reported in the literature. Here, we report the notable alteration in the metabolism of tacrolimus in two patients with hepatic VOD, in whom the half-lives of tacrolimus were markedly prolonged (288 and 146 h).

KW - Hematopoietic stem cell transplantation

KW - Hepatic VOD

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=28444481014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28444481014&partnerID=8YFLogxK

U2 - 10.1111/j.1432-2277.2005.00204.x

DO - 10.1111/j.1432-2277.2005.00204.x

M3 - Article

C2 - 16162110

AN - SCOPUS:28444481014

VL - 18

SP - 1215

EP - 1217

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 10

ER -